187 related articles for article (PubMed ID: 31831562)
1. Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells.
Lemm EA; Valle-Argos B; Smith LD; Richter J; Gebreselassie Y; Carter MJ; Karolova J; Svaton M; Helman K; Weston-Bell NJ; Karydis L; Williamson CT; Lenz G; Pettigrew J; Harwig C; Stevenson FK; Cragg M; Forconi F; Steele AJ; Cross J; Mackenzie L; Klener P; Packham G
Clin Cancer Res; 2020 Apr; 26(7):1700-1711. PubMed ID: 31831562
[TBL] [Abstract][Full Text] [Related]
2. Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies.
Kapoor I; Li Y; Sharma A; Zhu H; Bodo J; Xu W; Hsi ED; Hill BT; Almasan A
Cell Death Dis; 2019 Dec; 10(12):924. PubMed ID: 31801949
[TBL] [Abstract][Full Text] [Related]
3. Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 1. Effects on inflammatory cell activation and chemotaxis in vitro and pharmacokinetic characterization in vivo.
Stenton GR; Mackenzie LF; Tam P; Cross JL; Harwig C; Raymond J; Toews J; Wu J; Ogden N; MacRury T; Szabo C
Br J Pharmacol; 2013 Mar; 168(6):1506-18. PubMed ID: 23121445
[TBL] [Abstract][Full Text] [Related]
4. Targeted PI3K/AKT-hyperactivation induces cell death in chronic lymphocytic leukemia.
Ecker V; Stumpf M; Brandmeier L; Neumayer T; Pfeuffer L; Engleitner T; Ringshausen I; Nelson N; Jücker M; Wanninger S; Zenz T; Wendtner C; Manske K; Steiger K; Rad R; Müschen M; Ruland J; Buchner M
Nat Commun; 2021 Jun; 12(1):3526. PubMed ID: 34112805
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of SH2-Containing Inositol Phosphatase Contributes to Chronic Lymphocytic Leukemia Survival.
Pal Singh S; de Bruijn MJW; Velaso Gago da Graça C; Corneth OBJ; Rip J; Stadhouders R; Meijers RWJ; Schurmans S; Kerr WG; Ter Burg J; Eldering E; Langerak AW; Pillai SY; Hendriks RW
J Immunol; 2020 Jan; 204(2):360-374. PubMed ID: 31836657
[TBL] [Abstract][Full Text] [Related]
6. BTK and PI3K Inhibitors Reveal Synergistic Inhibitory Anti-Tumoral Effects in Canine Diffuse Large B-Cell Lymphoma Cells.
Kong W; Sender S; Taher L; Villa-Perez S; Ma Y; Sekora A; Ruetgen BC; Brenig B; Beck J; Schuetz E; Junghanss C; Nolte I; Murua Escobar H
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884478
[TBL] [Abstract][Full Text] [Related]
7. Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma.
He Y; Li J; Ding N; Wang X; Deng L; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Song Y; Zhu J
J Exp Clin Cancer Res; 2019 Feb; 38(1):86. PubMed ID: 30777096
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.
Erdmann T; Klener P; Lynch JT; Grau M; Vočková P; Molinsky J; Tuskova D; Hudson K; Polanska UM; Grondine M; Mayo M; Dai B; Pfeifer M; Erdmann K; Schwammbach D; Zapukhlyak M; Staiger AM; Ott G; Berdel WE; Davies BR; Cruzalegui F; Trneny M; Lenz P; Barry ST; Lenz G
Blood; 2017 Jul; 130(3):310-322. PubMed ID: 28202458
[TBL] [Abstract][Full Text] [Related]
9. Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies.
Cooney JD; Lin AP; Jiang D; Wang L; Suhasini AN; Myers J; Qiu Z; Wölfler A; Sill H; Aguiar RCT
Clin Cancer Res; 2018 Mar; 24(5):1103-1113. PubMed ID: 29246942
[No Abstract] [Full Text] [Related]
10. Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma.
Sasi BK; Martines C; Xerxa E; Porro F; Kalkan H; Fazio R; Turkalj S; Bojnik E; Pyrzynska B; Stachura J; Zerrouqi A; Bobrowicz M; Winiarska M; Priebe V; Bertoni F; Mansouri L; Rosenquist R; Efremov DG
Leukemia; 2019 Oct; 33(10):2416-2428. PubMed ID: 30872780
[TBL] [Abstract][Full Text] [Related]
11. Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 2. Efficacy studies in allergic and pulmonary inflammation models in vivo.
Stenton GR; Mackenzie LF; Tam P; Cross JL; Harwig C; Raymond J; Toews J; Chernoff D; MacRury T; Szabo C
Br J Pharmacol; 2013 Mar; 168(6):1519-29. PubMed ID: 23121409
[TBL] [Abstract][Full Text] [Related]
12. Activation of unfolded protein response overcomes Ibrutinib resistance in diffuse large B-cell lymphoma.
Zhang XT; Hu XB; Wang HL; Kan WJ; Xu L; Wang ZJ; Xiang YQ; Wu WB; Feng B; Li JN; Gao AH; Dong TC; Xia CM; Zhou YB; Li J
Acta Pharmacol Sin; 2021 May; 42(5):814-823. PubMed ID: 32855532
[TBL] [Abstract][Full Text] [Related]
13. SHIP1, but not an AML-derived SHIP1 mutant, suppresses myeloid leukemia growth in a xenotransplantation mouse model.
Täger M; Horn S; Latuske E; Ehm P; Schaks M; Nalaskowski M; Fehse B; Fiedler W; Stocking C; Wellbrock J; Jücker M
Gene Ther; 2017 Nov; 24(11):749-753. PubMed ID: 29143813
[TBL] [Abstract][Full Text] [Related]
14. Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia.
Manna A; Aulakh S; Jani P; Ahmed S; Akhtar S; Coignet M; Heckman M; Meghji Z; Bhatia K; Sharma A; Sher T; Alegria V; Malavasi F; Chini EN; Chanan-Khan A; Ailawadhi S; Paulus A
Clin Cancer Res; 2019 Jul; 25(13):3974-3985. PubMed ID: 30940652
[TBL] [Abstract][Full Text] [Related]
15. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.
Robak T; Robak P
Int Rev Immunol; 2013 Aug; 32(4):358-76. PubMed ID: 23617253
[TBL] [Abstract][Full Text] [Related]
16. AQX-1125, small molecule SHIP1 activator inhibits bleomycin-induced pulmonary fibrosis.
Cross J; Stenton GR; Harwig C; Szabo C; Genovese T; Di Paola R; Esposito E; Cuzzocrea S; Mackenzie LF
Br J Pharmacol; 2017 Sep; 174(18):3045-3057. PubMed ID: 28658529
[TBL] [Abstract][Full Text] [Related]
17. Naquotinib exerts antitumor activity in activated B-cell-like diffuse large B-cell lymphoma.
Tanaka H; Kaneko N; Sakagami H; Matsuya T; Hiramoto M; Yamanaka Y; Mori M; Koshio H; Hirano M; Takeuchi M
Leuk Res; 2020 Jan; 88():106286. PubMed ID: 31865062
[TBL] [Abstract][Full Text] [Related]
18. Small-molecule agonists of SHIP1 inhibit the phosphoinositide 3-kinase pathway in hematopoietic cells.
Ong CJ; Ming-Lum A; Nodwell M; Ghanipour A; Yang L; Williams DE; Kim J; Demirjian L; Qasimi P; Ruschmann J; Cao LP; Ma K; Chung SW; Duronio V; Andersen RJ; Krystal G; Mui AL
Blood; 2007 Sep; 110(6):1942-9. PubMed ID: 17502453
[TBL] [Abstract][Full Text] [Related]
19. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
Front Immunol; 2021; 12():766272. PubMed ID: 34912339
[TBL] [Abstract][Full Text] [Related]
20. B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells.
Seda V; Mraz M
Eur J Haematol; 2015 Mar; 94(3):193-205. PubMed ID: 25080849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
